Mill Creek Capital Advisors’s AbbVie ABBV Stock Holding History

Mill Creek Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$396K	Buy	1,821 +29	+2%	+$6.43K	0.01%	184
2025 Q4	$409K	Sell	1,792 -703	-28%	-$160K	0.01%	179
2025 Q3	$578K	Buy	2,495 +435	+21%	+$88.6K	0.01%	151
2025 Q2	$382K	Sell	2,060 -1,178	-36%	-$219K	0.01%	184
2025 Q1	$679K	Buy	3,238 +112	+4%	+$21.8K	0.02%	137
2024 Q4	$555K	Sell	3,126 -141	-4%	-$25.9K	0.01%	156
2024 Q3	$645K	Sell	3,267 -470	-13%	-$87.7K	0.02%	145
2024 Q2	$641K	Buy	3,737 +316	+9%	+$52.3K	0.02%	151
2024 Q1	$623K	Sell	3,421 -497	-13%	-$85.7K	0.02%	143
2023 Q4	$607K	Buy	3,918 +34	+0.9%	+$4.96K	0.02%	142
2023 Q3	$579K	Sell	3,884 -1,234	-24%	-$181K	0.02%	131
2023 Q2	$690K	Buy	5,118 +987	+24%	+$145K	0.02%	129
2023 Q1	$658K	Sell	4,131 -168	-4%	-$25.7K	0.02%	131
2022 Q4	$695K	Buy	+4,299	New	+$659K	0.03%	121

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Mill Creek Capital Advisors's ABBV Position: Q1 2026 in Review

Mill Creek Capital Advisors increased its AbbVie (ABBV) stake by 1.6% in Q1 2026, buying an estimated $6.43K and bringing the position to 1,821 shares worth $396K. The position accounts for 0.01% of the portfolio, ranked #184.

Mill Creek Capital Advisors first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $695K in Q4 2022. 4,103 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Mill Creek Capital Advisors held 1,821 shares of AbbVie worth $396K as of Q1 2026.
Mill Creek Capital Advisors bought 29 AbbVie shares in Q1 2026, an estimated $6.43K.
AbbVie made up 0.01% of Mill Creek Capital Advisors's portfolio in Q1 2026, its #184 holding.
Mill Creek Capital Advisors first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Mill Creek Capital Advisors's AbbVie position peaked at $695K in Q4 2022.
4,103 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Mill Creek Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.